Gsk Plc ADR (NY: GSK )

43.91 +0.17 (+0.39%)
Official Closing Price Updated: 7:00 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,129,097
Open 43.75
Bid (Size) 43.35 (2)
Ask (Size) 43.90 (44)
Prev. Close 43.74
Today's Range 43.53 - 43.98
52wk Range 33.67 - 45.92
Shares Outstanding 5,385,189,617
Dividend Yield 3.29%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Performance

YTD
+17.06%
+17.06%
1 Month
+10.77%
+10.77%
3 Month
+7.41%
+7.41%
6 Month
+3.46%
+3.46%
1 Year
+25.35%
+25.35%

More News

Read More
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
Is GSK a Top-Value Stock Right Now?
Via The Motley Fool
New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules
Via Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
Via Investor Brand Network
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
Via FinancialNewsMedia
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Via Investor's Business Daily
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Via Benzinga
Exposures COVID-19
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
From FN Media Group LLC
Via GlobeNewswire
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
From GSK plc
Via Business Wire
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
British Pharma Giant GSK's Blockbuster Shingles And Respiratory Syncytial Virus Vaccine Q2 Sales Miss Expectations, Cuts Annual Vaccine Revenue Guidance
Via Benzinga
Topics Earnings
Exposures Financial
GSK Beats Second-Quarter Views, Raises Outlook; But Shares Fall On Shingrix Miss
Via Investor's Business Daily
Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility
Via Benzinga
Topics Economy
Exposures Interest Rates
GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests
Via Benzinga
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Via Benzinga
3 Stocks Under $10 With the Potential for Massive Gains
Via InvestorPlace
Top Research Reports For Apple, Lowe's & Shopify
Via Talk Markets
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
Via Benzinga
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.